Johnson & Johnson
Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%
Johnson & Johnson COVID-19 Vaccine [reported through FY2024Q4] by Year
COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — Worldwide reported growth YoY (%) (%)
Johnson & Johnson COVID-19 Vaccine [reported through FY2024Q4]: -82.4% in FY2024, down 33.6 pts from a year earlier. No newer figure appears in the documents we track.
Where the FY2024 figure comes from
“|| WW | 198 | 1,117 | (82.4) | (82.4) | 0.0”
Source: Form 8-K (a2024q4exhibit991.htm, filed 2025-01-22) ↗
Reported in Form 8-K EX-99.2 Segment Sales Schedule.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — Worldwide reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2024 | Dec 29, 2024 | -82.4% | -33.6 pts | Form 8-K (a2024q4exhibit991.htm, filed 2025-01-22) ↗ |
| FY2023 | Dec 31, 2023 | -48.8% | -40.2 pts | Form 8-K (a2023q4exhibit991.htm, filed 2024-01-23) ↗ |
| FY2022 | Jan 1, 2023 | -8.6% | – | Form 8-K (a2022q4exhibit991.htm, filed 2023-01-24) ↗ |
Cite this data
StockData. (2026). Johnson & Johnson COVID-19 Vaccine [reported through FY2024Q4] (%), annual FY2022–FY2024 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-covid19-rep-yoy
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.